DBV Technologies S.A. (NASDAQ:DBVT – Get Rating) has earned a consensus rating of “Hold” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $7.00.
A number of research analysts recently weighed in on the stock. The Goldman Sachs Group lowered shares of DBV Technologies from a “neutral” rating to a “sell” rating in a report on Friday, December 16th. Societe Generale raised shares of DBV Technologies from a “hold” rating to a “buy” rating in a report on Wednesday, January 4th. Finally, StockNews.com assumed coverage on shares of DBV Technologies in a report on Wednesday. They issued a “sell” rating for the company.
DBV Technologies Price Performance
Shares of DBVT opened at $1.44 on Wednesday. DBV Technologies has a 1 year low of $1.08 and a 1 year high of $3.43. The company has a 50 day simple moving average of $1.41 and a two-hundred day simple moving average of $1.83. The firm has a market cap of $271.11 million, a P/E ratio of -2.62 and a beta of 1.29.
Institutional Trading of DBV Technologies
A number of institutional investors have recently bought and sold shares of the stock. Advisory Services Network LLC bought a new stake in DBV Technologies in the second quarter worth $26,000. Commonwealth Equity Services LLC bought a new stake in DBV Technologies in the third quarter worth $26,000. Two Sigma Investments LP lifted its position in DBV Technologies by 80.9% in the third quarter. Two Sigma Investments LP now owns 35,920 shares of the company’s stock worth $64,000 after buying an additional 16,066 shares during the last quarter. BNP Paribas Arbitrage SA bought a new stake in DBV Technologies in the second quarter worth $49,000. Finally, Optiver Holding B.V. bought a new stake in DBV Technologies in the third quarter worth $36,000. 18.37% of the stock is currently owned by institutional investors.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- When Will Crane Holdings Take Flight?
- 3 Retail Stocks Ringing the Register in 2023
- Is It Time To Get Aggressive With Defense Stocks?
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.